Fly News Breaks for September 20, 2017
XLRN
Sep 20, 2017 | 05:10 EDT
Barclays analyst Paul Choi raised his price target for Acceleron Pharma to $50 saying the company at its R&D day made a "good case for how it could gradually transform into a diversified biotech." The shares over the near term will remain tied to the luspatercept Phase 3 data sets in mid-2018, Choi tells investors in a research note. He believes the company is making progress with its pipeline and keeps an Overweight rating on the shares.
News For XLRN From the Last 2 Days
There are no results for your query XLRN